Search Results

You are looking at 121 - 130 of 2,852 items for :

  • Refine by Access: All x
Clear All
Full access

Microsatellite Instability and KRAS Mutation in Stage IV Colorectal Cancer: Prevalence, Geographic Discrepancies, and Outcomes From the National Cancer Database

Johannes Uhlig, Michael Cecchini, Amar Sheth, Stacey Stein, Jill Lacy, and Hyun S. Kim

prevalence of microsatellite and KRAS status in stage IV CRC using a large-scale US national database and assessed their effect on outcomes of patients with CRC. Materials and Methods This study received approval from the Yale School of Medicine

Full access

Refusal of Recommended Chemotherapy for Ovarian Cancer: Risk Factors and Outcomes; a National Cancer Data Base Study

Sumer K. Wallace, Jeff F. Lin, William A. Cliby, Gary S. Leiserowitz, Ana I. Tergas, and Robert E. Bristow

in patients with ovarian cancer Describe the impact on patient outcomes related to refusal of recommended chemotherapy in patients with ovarian cancer Background Ovarian cancer remains the deadliest gynecologic malignancy, with

Full access

HSR19-107: Nivolumab for Newly Diagnosed Classical Hodgkin Lymphoma: Patient-Reported Outcomes From CheckMate 205 Cohort D

Radhakrishnan Ramchandren, Stephen M. Ansell, Philippe Armand, Andreas Engert, Fiona Taylor, Kim Cocks, Clara Chen, Bryan Bennett, Alejandro Moreno-Koehler, Adam Roeder, Anne Sumbul, Mariana Sacchi, and David Cella

checkpoint inhibitor monoclonal antibody, demonstrated efficacy and clinically meaningful improvement in pt-reported outcomes (PROs) in pts with relapsed/refractory cHL in cohorts A, B, and C of CheckMate 205 (NCT02181738) (Armand et al, J Clin Oncol 2018

Full access

CLO19-027: Assessment of Metastatic Invasive Lobular Carcinoma Management and Outcomes From 2004-2014: A Single Institution Experience

Hinda Boutrid, Maryam Lustberg, Jeffrey Vandeusen, Sagar Sardesai, Daniel Stover, Robert Wesolowski, Mathew Cherian, Julie Stephens, Marilly Palettas, Evan Morgan, Mohmoud Kassem, Michael Berger, Craig A. Vargo, Bhuvaneswari Ramaswamy, and Nicole Williams

outcomes and treatment strategies of metastatic ILC. This retrospective study evaluates the overall survival (OS) and progression-free survival (PFS) in the metastatic ILC population at a single institution, focusing on first line treatment received in the

Full access

QIM19-129: Utilization of Electronic Medical Record to Improve Outcomes in the Treatment of Febrile Neutropenia

Anna M. Gibson and Claire Sutherby

Introduction: Chemotherapy-induced febrile neutropenia is a medical emergency. Delays in time to appropriate broad spectrum antibiotic therapy significantly increase morbidity and mortality. The purpose of this project is to improve outcomes in

Full access

HSR19-076: A Prospective Study of the Usage of Pain Medication, Cost, Alternative Medication Use, and Outcome by Cancer Patients in Real World

Praveen Adusumilli, Vidya Viswanath, and Raghunadha Rao Digumarthi

Introduction: Perception of pain and the need to treat it is highly variable, even amongst oncologists. Availability of pain specialists is an added advantage. This is an analysis of prescription patterns of pain medication and its outcome in

Full access

Vascular Invasion and Metastasis is Predictive of Outcome in Barcelona Clinic Liver Cancer Stage C Hepatocellular Carcinoma

Ali A. Mokdad, Amit G. Singal, Jorge A. Marrero, Hao Zhu, and Adam C. Yopp

for HCC remains below 20% in the United States. 2 Poor HCC outcomes are largely attributed to low rates of HCC surveillance and high rates of late stage diagnosis. 3 , 4 Accurate HCC staging is important for patient prognostication, treatment

Full access

Issues of Imatinib and Pregnancy Outcome

Jane Apperley

to have functions that may be important in gonadal development, implantation, and fetal development. 1 - 5 An international registry of pregnancy outcome was recently established by Novartis to compile pregnancy outcomes in women who have been

Full access

Predictors of Outcome in Bladder Cancer

John B. Eifler, Daniel A. Barocas, and Matthew J. Resnick

) remains low, and selecting the subset of patients most likely to benefit from NAC has proven difficult. Patients with organ-confined MIBC have experienced excellent oncologic outcomes absent the use of NAC (5-year disease-specific survival of ≈80%). 12

Full access

SupportScreen: A Model for Improving Patient Outcomes

Matthew Loscalzo, Karen Clark, Jeff Dillehunt, Redmond Rinehart, Rex Strowbridge, and Daniel Smith

authors have taken this process a step further by automating biopsychosocial screening through the use of touch-screen technology. 12 SupportScreen Improved Patient Outcomes “At Your Fingertips” The authors' team developed a new touch screen